Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because assorted short people are messaging us with questions, the official mascot is bounding about the campus grounds in search of varmints, and the to-do list is growing quickly. So this calls for action — firing up the coffee kettle to brew some cups of stimulation. Our choice today is pumpkin spice. Please feel free to join us. Remember, no prescription is required, so no rebate must be paid. Meanwhile, here are some tidbits. Have a smashing day and please do keep in touch. …

GlaxoSmithKline (GSK) chief executive officer Emma Walmsley has come under pressure from a second activist hedge fund, Bluebell Capital Partners, which has taken a stake worth about $14 million in the drug maker to push for change at the top, including demanding that she reapply for her job, The Guardian says. Earlier this year, the Elliott Management fund had also taken a stake in Glaxo, calling for a leadership change at the company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment